|
1
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Linehan WM and Ricketts CJ: The cancer
genome atlas of renal cell carcinoma: Findings and clinical
implications. Nat Rev Urol. 16:539–552. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Campi R, Rebez G, Klatte T, Roussel E,
Ouizad I, Ingels A, Pavan N, Kara O, Erdem S, Bertolo R, et al:
Effect of smoking, hypertension and lifestyle factors on kidney
cancer-perspectives for prevention and screening programmes. Nat
Rev Urol. 20:669–681. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ge W, Song S, Qi X, Chen F, Che X, Sun Y,
Wang J, Li X, Liu N, Wang Q and Wu G: Review and prospect of immune
checkpoint blockade therapy represented by PD-1/PD-L1 in the
treatment of clear cell renal cell carcinoma. Oncol Res.
31:255–270. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harrison H, Thompson RE, Lin Z, Rossi SH,
Stewart GD, Griffin SJ and Usher-Smith JA: Risk prediction models
for kidney cancer: A systematic review. Eur Urol Focus.
7:1380–1390. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Joerger AC and Fersht AR: Structural
biology of the tumor suppressor p53. Annu Rev Biochem. 77:557–582.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu D and Prives C: Relevance of the
p53-MDM2 axis to aging. Cell Death Differ. 25:169–179. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zavileyskiy L and Bunik V: Regulation of
p53 function by formation of non-nuclear heterologous protein
complexes. Biomolecules. 12:3272022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Guo M, Wei H and Chen Y: Targeting
p53 pathways: Mechanisms, structures, and advances in therapy.
Signal Transduct Target Ther. 8:922023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen JX, Xu D, Cao JW, Zuo L, Han ZT, Tian
YJ, Chu CM, Zhou W, Pan XW and Cui XG: TRIM47 promotes malignant
progression of renal cell carcinoma by degrading P53 through
ubiquitination. Cancer Cell Int. 21:1292021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jian W, Xue W, Wang T, Yu Y, Cai L, Meng
Y, Xia Z and Zhang C: RBM4 inhibits the growth of clear cell renal
cell carcinoma by enhancing the stability of p53 mRNA. Mol
Carcinog. 62:464–478. 2023. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fassler M, Benaim C and George J: TREM2
agonism with a monoclonal antibody attenuates tau pathology and
neurodegeneration. Cells. 12:15492023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Molgora M, Liu YA, Colonna M and Cella M:
TREM2: A new player in the tumor microenvironment. Semin Immunol.
67:1017392023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li RY, Qin Q, Yang HC, Wang YY, Mi YX, Yin
YS, Wang M, Yu CJ and Tang Y: TREM2 in the pathogenesis of AD: A
lipid metabolism regulator and potential metabolic therapeutic
target. Mol Neurodegener. 17:402022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katzenelenbogen Y, Sheban F, Yalin A, Yofe
I, Svetlichnyy D, Jaitin DA, Bornstein C, Moshe A, Keren-Shaul H,
Cohen M, et al: Coupled scRNA-Seq and intracellular protein
activity reveal an immunosuppressive role of TREM2 in cancer. Cell.
182:872–885.e19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park MD, Reyes-Torres I, LeBerichel J,
Hamon P, LaMarche NM, Hegde S, Belabed M, Troncoso L, Grout JA,
Magen A, et al: TREM2 macrophages drive NK cell paucity and
dysfunction in lung cancer. Nat Immunol. 24:792–801. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Sheng L, Tao J, Chen R, Li Y, Sun
Z and Qian W: Depletion of the triggering receptor expressed on
myeloid cells 2 inhibits progression of renal cell carcinoma via
regulating related protein expression and PTEN-PI3K/Akt pathway.
Int J Oncol. 49:2498–2506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. 8th edition. New
York: Springer; 2017
|
|
19
|
World Medical Association, . World medical
association declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salic A and Mitchison TJ: A chemical
method for fast and sensitive detection of DNA synthesis in vivo.
Proc Natl Acad Sci USA. 105:2415–2420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
24
|
Li C, Hou X, Yuan S, Zhang Y, Yuan W, Liu
X, Li J, Wang Y, Guan Q and Zhou Y: High expression of TREM2
promotes EMT via the PI3K/AKT pathway in gastric cancer:
Bioinformatics analysis and experimental verification. J Cancer.
12:3277–3290. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang J and Li Z: TREM2 is a prognostic
biomarker and correlated with an immunosuppressive microenvironment
in thyroid cancer. Dis Markers. 2022:18073862022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jung Y, Kraikivski P, Shafiekhani S,
Terhune SS and Dash RK: Crosstalk between Plk1 and p53, cell cycle,
and G2/M DNA damage checkpoint regulation in cancer: Computational
modeling and analysis. NPJ Syst Biol Appl. 7:462021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saha T, Solomon J, Samson AO and Gil-Henn
H: Invasion and metastasis as a central hallmark of breast cancer.
J Clin Med. 10:34982021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim SM, Kim EM, Ji KY, Lee HY, Yee SM, Woo
SM, Yi JW, Yun CH, Choi H and Kang HS: TREM2 Acts as a tumor
suppressor in colorectal carcinoma through Wnt1/β-catenin and Erk
signaling. Cancers (Basel). 11:13152019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang W, Lv B, Yang B, Chen Y, Yuan F, Ma
L, Chen S, Zhang S and Xia J: TREM2 acts as a tumor suppressor in
hepatocellular carcinoma by targeting the PI3K/Akt/β-catenin
pathway. Oncogenesis. 8:92019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Engeland K: Cell cycle regulation:
p53-p21-RB signaling. Cell Death Differ. 29:946–960. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu J, Peng Y and Wei W: Cell cycle on the
crossroad of tumorigenesis and cancer therapy. Trends Cell Biol.
32:30–44. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sabapathy K and Lane DP: Corrigendum to
‘understanding p53 functions through p53 antibodies’. J Mol Cell
Biol. 11:11052019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hernández Borrero LJ and El-Deiry WS:
Tumor suppressor p53: Biology, signaling pathways, and therapeutic
targeting. Biochim Biophys Acta Rev Cancer. 1876:1885562021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen L, Liu S and Tao Y: Regulating tumor
suppressor genes: Post-translational modifications. Signal
Transduct Target Ther. 5:902020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shamloo B and Usluer S: p21 in cancer
research. Cancers (Basel). 11:11782019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lei X, Gou YN, Hao JY and Huang XJ:
Mechanisms of TREM2 mediated immunosuppression and regulation of
cancer progression. Front Oncol. 14:13757292024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S,
Wu J, Liu J, Zou F, Wei J, et al: TREM2+ macrophages
suppress CD8+ T-cell infiltration after transarterial
chemoembolisation in hepatocellular carcinoma. J Hepatol.
79:126–140. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun R, Han R, McCornack C, Khan S, Tabor
GT, Chen Y, Hou J, Jiang H, Schoch KM, Mao DD, et al: TREM2
inhibition triggers antitumor cell activity of myeloid cells in
glioblastoma. Sci Adv. 9:eade35592023. View Article : Google Scholar : PubMed/NCBI
|
